Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + retlirafusp alfa + recaticimab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Adebrelimab + retlirafusp alfa + recaticimab + chemotherapy is a neoadjuvant combination regimen being investigated for the treatment of resectable non-small cell lung cancer (NSCLC). The regimen evaluates the efficacy of combining immune checkpoint inhibition—using either the PD-L1 inhibitor adebrelimab or the bifunctional PD-L1/TGF-β fusion protein retlirafusp alfa (SHR-1701)—with the PCSK9 inhibitor recaticimab (SHR-1209) and standard platinum-based chemotherapy. The rationale for this combination is based on preclinical evidence suggesting that PCSK9 inhibition can synergize with PD-1/PD-L1 inhibitors to suppress tumor growth, potentially by enhancing MHC-I expression and T-cell infiltration. The addition of TGF-β blockade via retlirafusp alfa aims to further overcome immune evasion in the tumor microenvironment. This multi-drug approach is currently in Phase II clinical development.
- Brand names
- Adely
- Other names
- Adebrelimab, Retlirafusp alfa, Recaticimab and chemotherapy
02
Targets
TGFB (GARP–latent transforming growth factor beta 1 complex)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on adebrelimab + retlirafusp alfa + recaticimab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + retlirafusp alfa + recaticimab + chemotherapy.